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ABSTRACT
Pyruvate is produced in duplicate at the end of glycolysis in addition to ATP and NADH.
Pyruvate is the metabolite of choice in most cells, whether obtained exogenously or
endogenously. Recently we found that the addition of pyruvate’s conjugate base, sodium
pyruvate, to cell culture media dampened the immune response to influenza A virus (IAV)
infection in cultured innate immune cells. Thus, I decided to investigate the mechanism and
potential for treatment of IAV. In vitro using bone marrow derived macrophages that were
infected with IAV we found that adding sodium pyruvate to the media decreased immune
signaling pathways through a decrease in pro-inflammatory cytokines (IL-6, IL-1β, and TNF-α).
Additionally, exogenous sodium pyruvate added to the infection media of macrophages,
diminished the mitochondrial reactive oxygen species production, without inhibiting virus
replication in vitro. To investigate the metabolite’s effects in vivo, we used C57Bl/6J mice to
establish a model for sodium pyruvate treatment during IAV infection. We used a moderate
infectious dose of IAV at 250PFU. We began by injecting the mice twice daily with diluted
sodium pyruvate. While overall animal activity increased, no differences in proportional weight
loss between saline controls and sodium pyruvate treated groups were observed. IAV is a
respiratory virus and sodium pyruvate a metabolite of choice for cells; therefore, targeting the
treatment to the respiratory tract with nebulizer treatments three times a day showed a significant
difference (Days 7-14 post infection) in proportional weight loss. Sodium pyruvate treated mice
were found to lose less mass, consume more chow, and feel better overall. Sodium pyruvate
nebulized mice had decreased viral titer and decreased pro-inflammatory cytokines 7 days postinfection as well. Conclusively, sodium pyruvate ameliorates IAV infection in vitro and in vivo.

KEYWORDS: influenza A virus, inflammation, inflammasome, pyruvate, NOD-like receptor
(NLR), metabolite, immunometabolism
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OVERVIEW

Disclaimer
This work is the result of a collaborative effort with Hazar Abusamalah (spelled Hazzar
Abysalamah in BearWorks Institutional Repository, MSc graduate thesis, May 2018). In my
second chapter, Hazar and I worked collaboratively to publish this manuscript (now in press).
We both used C57Bl/6J mice to obtain bone marrow for BMDM cell culture, influenza
A/PR/8/34 H1N1, sodium pyruvate (NaPyr), and media/additives for all experiments.
Additionally, Hazar’s thesis includes methods used throughout the project by both her and I.
Hazar’s data for cell death, mitochondrial damage (reactive oxygen species), and viral replication
were used to publish this manuscript, and are included here (page 29, Figure 1 D-G). Hazar
tested the effects of different glycolysis inhibitors, 2 deoxy-glucose or hemagglutinin. She then
tested E. coli and Aspergillus fumigatus, where I tested for Poly I:C, and both looked at
LPS+ATP as alternative infections. Additionally, I tested for intracellular ATP and lactate
production and interferon-β production in samples. I replicated ELISA and western blot samples
to increase the appropriate sample size for statistical analysis. Our theses differ in the methods by
Hazar’s IAV cultivation, her testing the difference in glycolysis inhibitors and infection of
BMDM with Aspergillus fumigatus. This is replaced in my thesis by intracellular ATP, lactate
production, and treatment/infection with Poly I:C. Consequently, the results vary the same as the
methods. In summation, I continued the in vitro work in BMDMs. In addition, I introduced the
work in mice, in vivo, which can be found in my third chapter (second manuscript, now in press).
Chapter 3 is solely my work, built on top of Hazar and my collaboration of in vitro work. Both
studies suggest that NaPyr may be an alternative therapy to IAV infection.
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Background
Influenza A Virus (IAV), commonly known as the flu virus, has an impact on human life
annually. IAV continues to plague the population and while anti-viral treatments are available,
they are prone to viral resistance by mutations in the viral RNA. The influenza vaccine is
available annually, but the most recent vaccine covers only four variants of the thousands of
influenza variants in the world [1] and only 48.4% of the United States population 18 years or
older received the vaccine in the 2019-2020 flu season [2]. Years where the vaccination rates are
low puts a heavy burden on anti-viral therapies to help with the IAV infections. However, those
therapies target specific components of the virus and are prone to viral resistance.
From our study, one potential alternative to these anti-viral treatments would be the
metabolite sodium pyruvate (NaPyr). Pyruvate (Pyr) is the end product of glycolysis. Pyruvate
has two fates for energy production. When oxygen is present aerobic glycolysis occurs, which
then can be used for energy production via a series of pathways, the citric acid cycle, electron
transport chain, and oxidative phosphorylation, which ends in the most efficient energy
production [3]. Alternatively, glycolysis can occur anaerobically where lactate dehydrogenase
converts pyruvate to lactate. Lactate can then be exported out of the cell. However, anaerobic
glycolysis leads to decreased ATP efficiency through lactic acid fermentation [4]. Therefore,
using aerobic glycolysis and oxidative pathways is more efficient leaving Pyr as an essential
component of cellular metabolism (Figure 1). Using a universal metabolite, such as Pyr, to
enhance the innate immune response would decrease the concerns that are observed from using
other anti-viral treatments that target specific components or intricacies of the virus. Targeting
specific pieces of the virus is likely to lead to virus mutation, which ultimately renders the antiviral treatment useless against the resistant virus.
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This project hails from a moment of serendipity, in which two different bottles of media
were used to culture innate immune cells. These two experiments yielded differing results
between the same treatment groups based on the media used. The only difference was that one
bottle of media contained NaPyr, and the other did not. From this preliminary observation, it was
found that the addition of NaPyr to the media seemed to dampen the immune response to
influenza A virus (IAV) in macrophages. From there, we continued to investigate the possible
mechanisms in which NaPyr might be immunomodulating the disease associated with IAV
infection. Hazar Abusalamah’s groundwork was the foundation of the in vitro work and
demonstrated that NaPyr does have an effect on inflammasome activation and subsequent
immunomodulatory responses in murine bone marrow derived macrophages (BMDM) [5].
Recognizing some of the mechanism in vitro, we continued to develop a mouse model for
treatment with NaPyr over the course of IAV infection.

Influenza Virus
How influenza invades. There are four types of influenza virus; three of which are
currently infectious to humans: A, B, and C [6]. Influenza C causes only mild illness, but
influenza A and B are the perpetrators for our annual flu season. IAV is well known to cause
deadly pandemics, because of its zoonotic capabilities, such as the 1918 Spanish flu, or the 2009
H1N1 pandemic [7]. Part of the Orthomyxoviridae family, IAV has a segmented genome with
eight segments of negative sense viral RNA that codes its 10 structural proteins and some nonstructural proteins [8, 9]. The virus is encapsulated in a lipid viral envelope, which is derived
from the host cell’s phospholipid bilayer, which it acquires upon exit and serves to protect all the
viral components from the external environment while the virus moves to its next
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destination [10]. Protruding from the lipid viral envelope are two primary surface glycoproteins.
When IAV encounters a cell, hemagglutinin (HA), one of two primary surface glycoproteins,
must bind with sialic acid, IAV’s receptor molecule on the target cell [11]. Once HA has fused
with sialic acid the virus becomes endocytosed and is now trapped within the endosome inside of
the cell, where the endosome is directed to travel close to the nucleus [12, 13]. The endosome
becomes acidic which activates the M2 proton channel protein [14]. The lipid viral envelope and
endosome then fuse, and a pore is formed for the viral ribonucleoprotein particles (RNPs) to be
released into the cytoplasm. The RNA is then translocated to the nucleus [12, 15]. While in the
nucleus, transcription and replication of the viral genome begins. Once the genomic replication
has been completed, the virus needs to make it to the cell’s membrane to become enveloped.
Neuraminidase (NA), the other primary surface glycoprotein, is an enzyme that helps the virus
escape the infected host cell. NA cleaves the terminal α-sialic acid residues that remain on the
cell’s surface to prevent subsequent infection by daughter virions, as well as helping the newly
formed virions move on to infect new cells or even new hosts [16]. Another suggested potential
use of NA is that it may aid in HA fusion in human airway epithelium [17].
Naming and genomic changes. The two primary surface glycoproteins, HA and NA, are
the method in which we name IAVs, for example H1N1 or H7N15. This is important, because
IAVs are prone to antigenic drift and antigenic shift. Antigenic drift is recognized as random
minor changes within the HA and NA protein structures [16]. These changes can be caused by
subtle mistakes made during viral replication. In turn, antigenic shift is known as major changes
in the in the protein structures. These changes are large reassortments of different IAV subtypes
that happen when two different IAVs infect the same host cell at the same time. For instance, if
the H1N1 and H7N15 viruses just mentioned infected the same cell, they could reassort creating
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H1N15 or H7N1 viruses. Both drift and shift can result in disease outbreaks; however, shift is
more likely to create combinations that the naïve human immune system has never seen.
Therefore, antigenic shift is more likely to evade the immune response and result in pandemics,
such as the 2009 H1N1 pandemic [16].

The Immune System and How it Recognizes IAV
Innate Immune Cells. The immune system is comprised of two parts: the innate and the
adaptive immune system. The innate immune system is the first line of defense of the two-phase
immune system. Many cells are considered part of the innate immune system and are able
to detect foreign particles, such as dust, viruses, bacteria, etc. These cells belong to a larger class
of cells known as leukocytes, or white blood cells, and are derived from hematopoietic stem
cells. Leukocytes include antigen presenting cells, such as dendritic cells and macrophages, as
well as lymphocytes [18]. The response from the cells of the innate immune system is typically
robust and indirect. For example, macrophages can be embryonic yolk-sac or embryonic
hematopoietic stem cell (HSC) derived and persist as resident macrophages in the tissue of
choice or can be recruited from HSC found in the bone marrow [19, 20]. Macrophages, also
contain the inflammasome, which can promote the secretion of many pro-inflammatory signaling
molecules, known as cytokines, which ultimately induce inflammation, circulate through the
host, and potentially cause tissue damage. Macrophages are also phagocytes, known as “the big
eater”, which engulf foreign particles and digest them [21, 22]. Through Major
Histocompatibility Complex (MHC) class I, which is present on all nucleated cells, and MHC
class II, which is present on “professional” antigen presenting cells, the macrophage activates the
adaptive immune system’s lymphocytes [23]. Lymphocytes are a subset of leukocytes that
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includes B and T cells. The T cell is activated through the junction of the T cell receptor and the
MHC class I and II on the antigen presenting cell (APC) and further stimulated by
cytokines (Figure 2) [24].
Pathogen Recognition and Inflammasome Activation. Pattern Recognition Receptors
(PRRs) are present on the surface of epithelial and immune cells that discern the difference
between self and non-self-materials. PRRs are poised to detect Pathogen Associated Molecular
Patterns (PAMPs), such as viral RNA from IAV. Toll like receptors (TLR) are subsets of PRRs
which contain leucine-rich repeat domains (LRRs) and upon stimulation send signals inside of
the cell to stimulate an immune response [25]. TLR7, an endosomal receptor, is essential in
identifying single stranded RNA (ssRNA). TLR3, another intracellular receptor, is a potent
identifier of double stranded RNA (dsRNA) within the endosome and is valuable in mounting an
immune response from respiratory tract cells [26]. Additionally, the activation of TLR3 and
TLR7 can lead to the activation of Nuclear Factor kappa-light-chain-enhancer of activated B
cells (NF-κB) [27]. Activation of either TLR3 or 7 triggers the signaling cascade with Myeloid
differentiation primary response gene 88 (MyD88) with Interleukin-1 receptor associated kinase
1 (IRAK4) and TNF receptor-associated factor 6 (TRAF6), which ultimately activates NFκB, which leads to the production of pro-inflammatory cytokines like IL-6, IL-1β, and TNFα [28, 29]. Another NF-κB activator is the retinoic acid-inducible gene-I (RIG-I)-like receptors
(RLRs). Unlike TLR3 and 7 in the endosome, RIG-I is important for sensing negative
sense ssRNA of IAV in the cytoplasm. Once RIG-I senses the IAV’s ssRNA, it interacts with the
mitochondrial adaptor signaling protein, MAVS, which can then induce the production of type I
interferons and other antiviral genes [30]. NF-κB and many diverse stimuli, including
mitochondrial reactive oxygen species (ROS), are potent activators of the NOD-like receptor
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containing pyrin 3 (NLRP3) inflammasome. The NLRP3-inflammasome (Figure 3) is initiated
by binding with the adaptor protein apoptosis-associated speck-like protein containing caspase
activation and recruitment domain (ASC) [31], which recruits pro-Caspase-1 and pro-IL-1β for
processing to their active forms [32, 33]. Active Caspase-1 induces pyroptosis, a form of
inflammatory programmed cell death, as well as causing the enzymatic cleavage of pro-IL-1β
and pro-IL-18 to their active forms of IL-1β and IL-18 [33, 34]. Both cytokines go on to create
an inflammatory response to infection.
The immune system and metabolism interface. Glycolysis is a well-regulated pathway
in which glucose-6-phosphate is broken down to produce ATP, NADH, and pyruvate. Pyruvate
then has two primary fates, oxidative phosphorylation or lactic acid production. When oxygen is
present, pyruvate is shuttled to the mitochondria where it enters the tricarboxylic acid cycle
(TCA) as Acetyl-CoA and can be used to produce more ATP (Figure 1). IAV increases glucose
uptake and aerobic glycolysis in infected cells to enhance glucose metabolism, which
demonstrates IAV’s dependency on the host cell’s machinery [35, 36]. Pyruvate can be
fermented to lactic acid, which has been shown to have antagonistic effects on RIG-I’s anti-viral
functions by binding to MAVS [4]. An alternative branch of glycolysis is the pentose phosphate
pathway (PPP); the PPP is known to aid with the production of sugars that make up nucleic
acids, but not ATP. During IAV infection, we observe an enhancement in the PPP, as it helps the
virus replicate its own nucleotides, which results in a decrease of cellular protein production. In
addition to the decreased cellular proteins, a decrease in lipids is observed as well. Driven by the
virus’s replication, cells increase the biosynthesis of lipids, as the virus takes a piece of the
phospholipid bilayer with it as it exits, and pro-inflammatory lipids increase in response to IAV
infection [35-37]. Overall, IAV infection diminishes a cell’s resources to replicate itself and to
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mount an immune response to the infection. Those resources are necessary for the cell to
maintain homeostasis before, during, and after the cell is infected.

Questions and Hypotheses
To combat issues such as viral resistance, mutation, and antigenic drift/shift caused by
the use of anti-viral treatments, other treatments need to be explored. As viral resistance gains a
foothold and the virus variant spreads, it renders the old anti-viral treatment useless. Hence there
is a need for more extensive research on universal metabolites, such as Pyr, and their ability to
combat viral infections, such as IAV. Universal metabolites with antioxidant capacity could,
potentially, be used prophylactically without the fear of anti-viral resistance. More extensive
studies were, and are, necessary to determine the ability and efficacy of NaPyr to act as an
immunomodulator and ameliorator of IAV symptoms, both in vitro and in vivo.
I proposed the two following hypotheses regarding NaPyr’s ability to dampen the
immune response to IAV infection:
Hypothesis one: Infecting murine bone marrow derived macrophages (BMDMs) with
IAV and treating them with varying concentrations of NaPyr (2µL, 5µL, and 10µL) would yield
differing immunomodulatory effects, because the additional NaPyr will fill the metabolic
deficiency caused by the virus’s replication preventing cellular damage and reducing immune
signaling. Alternatively, treating cells with NaPyr may increase lactic acid, which subsequently
inhibits RIG-I activation, as noted above, resulting in decreased immune signaling.
Hypothesis two: Since the treatment of IAV-infected BMDMs with NaPyr dampens the
immune response, then I hypothesized that administering NaPyr to C57Bl/6J mice infected with
IAV would lead to an improvement in health of infected animals and improved survival.
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Figure 1: Pyruvate is produced by glycolysis and can be shuttled to produce many other things.
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Figure 2: Macrophage (APC) phagocytosing and displaying IAV antigen to a T cell via the MHC
II/T cell receptor complex.
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Figure 3: The NLRP3 inflammasome and how the 3 in vitro activators/infections initiate
inflammasome induced inflammation.
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Figure 4: In vitro infection schemes to produce bone marrow derived macrophages, infect, and
analyze samples.
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Figure 5: In Vivo schemes for nebulizer treatments and tissue collections.
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PYRUVATE AFFECTS INFLAMMATORY RESPONSES OF MACROPHAGES
DURING INFLUENZA A VIRUS INFECTION

Abstract
Pyruvate is the end product of glycolysis and transported into the mitochondria for use in
the tricarboxylic acid (TCA) cycle. It is also a common additive in cell culture media. We
discovered that inclusion of sodium pyruvate in culture media during infection of mouse bone
marrow derived macrophages with influenza A virus impaired cytokine production (IL-6, IL-1β,
and TNF-α). Sodium pyruvate did not inhibit viral RNA replication. Instead, the addition of
sodium pyruvate alters cellular metabolism and diminished mitochondrial reactive oxygen
species (ROS) production and lowered immune signaling. Overall, sodium pyruvate affects the
immune response produced by macrophages but does not inhibit virus replication.

Introduction
Pyruvate (Pyr) (C3H4O3) is a central molecule in cellular metabolism. In addition to the
typical glycolysis-to-TCA pathway [1], Pyr can be derived from lactate taken up from outside
the cells or synthesized intracellularly from amino acids [2, 3]. Instead of entering the TCA
cycle, anaerobic glycolysis can occur (fermentation) where Pyr is reduced into lactate in order to
regenerate NAD+. In rapidly dividing cells, like some immune cells or cancer cells, this also
occurs even when oxygen is present (aerobic glycolysis/Warburg effect) [4]. Although
energetically less favorable, aerobic glycolysis facilitates metabolite production necessary for
rapid cell division, such as amino acid and nucleic acid synthesis [5]. Reports have shown that
IAV infection severely alters metabolism including amino acid and lipid metabolism [6].
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The innate immune system has germline-encoded pattern-recognition receptors (PRRs).
These sensors are capable of recognizing microorganisms that invade the host [7]. PRRs can
bind to pathogen-associated molecular patterns (PAMPs) such as RNA from viral genomes [8].
Detection of PAMPs by PRRs activates a variety of immune signaling pathways resulting in
cytokines production, increased phagocytosis and cell death. However, these responses can be
modulated by metabolic processes. When retinoic acid inducible gene-I (RIG-I) is activated by
cytoplasmic viral RNA, it moves to the mitochondria, where it interacts with mitochondrial
antiviral signaling protein (MAVS) [9]. MAVS then recruits adaptors proteins at the
mitochondria forming the MAVS signalosome, which activates the transcription factors IRF3/7
and NF-κB [10]. However, lactate can inhibit this pathway, thus dampening inflammation during
viral infection [11].
The inflammasome is another immune signaling pathway that forms a multiprotein
complex, which activates the cysteine protease caspase-1 [12]. Active caspase-1 then activates
the inflammatory cytokines interleukin (IL)-1β and IL-18 [13]. Inflammasome activation by
NOD-like receptor containing a pyrin 3 (NLRP3) is somewhat unique, as its main activation
signals are cellular damage including oxidative stress and potassium efflux [14, 15]. Intriguingly,
NLRP3 appears to be tuned-in to the metabolic state of cells through glycolysis [16, 17].
Pyr is well studied in metabolism, but its role in the immune response is not. During the
course of infecting macrophages with IAV, we noted that different brands of cell culture media
with different nutrient compositions affected the magnitude of the immune response. In
particular, the inclusion of sodium pyruvate (NaPyr) in culture media inhibited immune signaling
during IAV infection. Here we show that NaPyr added to BMDM cell culture media inhibits the
release of important pro-inflammatory cytokines IL-1β, IL-6, and TNF-α. In addition to these
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findings, we observed that addition of NaPyr does not inhibit viral replication, rather it
suppresses the immune response to IAV through altering metabolism and ROS production.

Materials and Methods
Animal Welfare. WT C57BL/6J mice were bred and raised in the Temple Hall Vivarium
at Missouri State University. Mice were euthanized via CO2 asphyxiation and cervical
dislocation, and bone marrow collected for differentiation into macrophages. All breeding and
experiments were performed in accordance with Institutional Animal Care and Use Committee
(IACUC) guidelines (protocols 16.009, Appendix C and 19.019, Appendix A), the AVMA
Guidelines on Euthanasia, NIH regulations (Guide for the Care and Use of Laboratory Animals),
and the U.S. Animal Welfare Act of 1966.
Generation of Bone Marrow Macrophages. Bone Marrow Derived Macrophages
(BMDM) were produced by harvesting bone marrow from the femur and tibia of 7-14-week-old
C57BL/6J mice. Bone marrow cells were then grown for 5 days in bone marrow differentiation
media (BMDM media), which consisted of Dulbecco's Modified Eagle Medium (DMEM) + 10%
FBS + 1% Pen/Strep + 1% Non-essential amino acids (NEAA) and supplemented with L929 cell
conditioned media. L929 cell conditioned medium contains Macrophage colony-stimulating
factor (M-CSF) and was produced by growing L929 cells in DMEM+ 10% FBS+ 1% Pen/Strep
for 10 days and then filtering the media via a 0.2μm filter.
On day 5 of BMDM growth, cells were scraped and re-plated into 12-well plates at 1x106
cells/well in 1ml BMDM media and incubated overnight to allow cells time to adhere to the
plates. Macrophages were used the following day for experiments as described below.
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Virus Production. The strain of IAV used in all experiments is influenza A/PR/8/34
H1N1 (Appendix B). In order to generate virus, we inoculated pathogen-free hen’s eggs with
1000 PFU of IAV. Three days post inoculation, the allantoic fluid was harvested, centrifuged to
remove debris, and frozen at -80°C for later use.
Viral Plaque Assay. To determine the viral titer of NaPyr treated or non-treated IAV
infected BMDM, IAV plaque assays were performed using Madin-Darby Canine Kidney
(MDCK) cells seeded at 3x105 cells/well in 12-well plates in DMEM+ 5% FBS+ 1%Pen/Strep.
10-fold dilutions of the virus were prepared in MEM without FBS. MDCK cells were washed
with PBS twice and 100µl of each virus dilution was added to duplicate wells in 12-well plates
and incubated at 37oC and 5% CO2 for one hour. Semisolid overlay was prepared as previously
described [18]. To allow for virus replication, TPCK-trypsin was added to a final concentration
of 1.0 µg/ml. After the full hour of incubation, infection medium was removed from the 12-well
plates, and 2ml of the warm overlay with TPCK trypsin was added to each well and allowed to
solidify. Plates were turned upside down and incubated for 3 days. After 3 days, the overlaid
agar was removed, and plaques counted after staining with 1% crystal violet in methanol.
Enzyme-Linked Immunosorbent Assay (ELISA). Cell culture supernatants collected
from infected and control BMDM were analyzed for IL-1β, TNF- α, and IL-6. ELISA kits were
purchased from Ebioscience (88-7013-88, 88-7324-88, 88-7064-88) and assays performed
according to the manufacturer’s recommendations. Plates were read at 450nm on a microplate
reader (BioTek ELx808).
Western Blotting. Cell lysates were collected by adding RIPA buffer with protease and
phosphatase inhibitors (Thermo Scientific, PIA32959, PIA32957) to BMDM treated and/or
infected as indicated. 4x SDS loading dye was then added to samples, which were boiled for 20
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minutes and resolved by SDS-PAGE and then transferred to PVDF membranes. Western blotting
for caspase-1 (caspase-1 p45 and p20), phosphorylated IκBα and total IκBα were then performed
by incubating membranes in primary antibody diluted in 5% milk in TBST overnight at 4 0C
(See Table 1 for a list of antibodies). The next day, membranes were washed 3x in TBST buffer
and incubated for 45 minutes in secondary antibody diluted in 5% milk in TBST (Table 1).
Membranes were washed again, and images obtained using Super Signal West Fempto substrate
(ThermoFisher, A53225) and an Azure C300 digital imaging system.
Cell Death and ROS. Macrophages were plated in 12-well plates and infected and/or
treated as indicated. After 24 hours, and 30 minutes before collecting samples, cells were stained
with a mitochondrial specific ROS sensitive dye (2.5nM Mitosox; ThermoFisher, M36008) or a
cell death stain (5 mM SYTOX-red; ThermoFisher, S34859). After 30 minutes, the media was
removed and 1ml of PBS was added to each well and the macrophages were scraped off the
wells. Cells were analyzed on an ACURI C6 or Attune NxT flow cytometer. Cells (10,000 per
sample) were analyzed for fluorescence intensity and percentage of cells positive for each dye.
Analysis of Gene Expression. BMDM were infected and treated as indicated and
samples were collected at 6, 12, and 24 hours after infection. Media was removed and 500µl
Trizol (Invitrogen, AM9738) was added to samples and incubated for 5 minutes at room
temperature. RNA was then isolated according to the manufactures protocol. All samples were
normalized to 200ng/μl RNA in nuclease-free water. The High Capacity cDNA Reverse
Transcriptase kit (Thermo Fisher Scientific 436881) was then used to convert 1ug RNA into
cDNA. Then, cDNA was diluted 1:5 in nuclease-free water, and 5 µl cDNA was used per
reaction to perform qRT-PCR with the DyNAmo HS SYBR Green qPCR master mix (Thermo
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Scientific 00596849) according to the manufacturer’s instructions using a STRATAGENEMx3005P PCR machine. (See Table 2 for Primer Sequences).
Examination of Cellular ATP. BMDM were infected and treated as indicated, with IAV
infected samples collected at 12 and 24 hours post infection. LPS + ATP samples were collected
at 4 hours post LPS treatment with ATP added for the final 30 minutes. Samples were analyzed
using a StayBrite Highly Stable ATP Bioluminescence Assay kit (BioVision, K791-100)
according to the kit instructions. To collect cell samples, the culture supernatant was removed,
cells were washed 3x with 5ml DPBS, and then, 100µl of 1X RIPA buffer was added to each
well. Cells lysate was collected and centrifuged at 12,000xg for 30 seconds. 10 µl of each cell
lysate was pipetted into enzyme/buffer mix, and then analyzed quickly using the GloMax Jr. by
ProMega on the GloBrite module, in RLUs.
Lactate Production Assay. BMDM were infected and treated as indicated and the
supernatant collected at 24 hours post infection. The supernatant samples were then centrifuged
at 14,000xg for 1 minute to remove cell debris. Samples were analyzed using the Eton
Bioscience L-Lactate Assay kit I (SKU# 1200011002) according to kit directions. Plates were
read at 490nm on a microplate reader (BioTek ELx808).
In Vitro Pyruvate Treatment. 1x106 macrophages were plated in 12-well plates
overnight. The next day, cells were washed 2x with PBS. Then, 200µl of RPMI 1640 without
serum or NaPyr and with L-glutamine was added to BMDM. Then 2.5 x 107 PFU of IAV
(25MOI) was added to some wells and other wells were left uninfected as controls. Uninfected
controls and IAV infected BMDM were also either untreated or treated with 1mM NaPyr
(HyClone, SH30239.01). Plates were incubated at 37 0C and 5% CO2 for two hours with shaking.
Then, 200µl RPMI +20% FBS was added to each well. The delayed addition of FBS is required
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for IAV infection of BMDM. Additional NaPyr was added to appropriate wells to maintain the
1mM concentration. Samples were collected at 6, 12, and 24 hours after IAV infection.
To test the effects of NaPyr on the immune response of BMDM to other stimuli, 1x106
BMDM were plated per well in 12-well plates. The next day, BMDM were washed 2x with PBS
and 400µl of RPMI 1640 with L-glutamine + 10% FBS, but without NaPyr was added to each
well. Some wells were treated with 1µg/ml LPS for 4 hours with inclusion of 5mM ATP (Sigma,
L3129 and Acros, 102800100) for the last 30 minutes. Some wells were also treated with 1, 2 or
5mM NaPyr. Samples were collected at the end of 4 hours of treatment. Poly I:C samples were
treated with 25µg/ml as indicated above and supernatants collected 24 hours post treatment.
Statistical Analysis. Statistical analysis was performed using GraphPad PRISM6.
Comparison of 2 conditions was performed using the 2-sided student’s t-test. Comparison of
multiple conditions was performed using the One-Way ANOVA with Tukey’s post-hoc test. A
p-value <0.05 was considered statistically significant.

Results
NaPyr Affects the Immune Response, Not virus Replication. In discussion with other
researchers (personal communication, Teneema Kurikose, St Jude Children’s Research
Hospital), we discovered the use of media from different suppliers impacted the magnitude of the
immune response by bone marrow derived macrophages (BMDM) during IAV infection.
Specifically, BMDM infected with IAV in Dubelco’s Modified Eagle’s Medium (DMEM)
purchased from Sigma Aldrich (Catalogue # D5671) produced elevated cytokine responses
compared to IAV infected BMDM cultured in DMEM purchased from ThermoFisher Scientific
(Corning MT10013CV or Gibco11995040). We also noted that bone marrow derived dendritic
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cells (BMDC) generally produce higher cytokine levels than BMDM in response to IAV
infection, but BMDC are typically cultured in RPMI 1640. We examined the composition of
these media and determined that NaPyr was associated with lower immune responses. Therefore,
we infected BMDM with IAV in RPMI1640 medium with and without NaPyr. Our data
demonstrate that addition of NaPyr significantly impaired cytokine production by BMDM
infected with IAV (Figure 1A-C).
We next examined virus replication by collecting cell culture media from infected
BMDMs 24h after infection and performing viral plaque assays. BMDM are refractory to
infection with some strains of IAV [19], but similar levels of functional virions were recovered
from BMDMs in our model with or without NaPyr treatment (Figure 1D). As virion production
was low overall, via qRT-PCR we further confirmed that NaPyr did not affect virus growth or its
ability to infect macrophages by examining viral RNA levels (IAV M1 and NP genes). NaPyr
did not inhibit the replication of virus RNA, demonstrating that NaPyr does not affect cytokine
responses by inhibiting IAV replication (Figure 1E-F). In addition, NaPyr treatment of IAV
infected BMDM had no effect on cell death (Figure 1G).
NaPyr Inhibits immune signaling pathways. We examined cytokine gene expression
by qRT-PCR at 6, 12, and 24h after IAV infection. NaPyr did have an inhibitory effect on gene
expression in IAV infected BMDM compared to virus infected BMDM cultured in the absence
of NaPyr (Figure 2A-D). We performed western blotting on cell lysates from BMDM infected
with IAV and treated with NaPyr but did not observe any significant differences in the activation
of NF-κB (phospho-IκBα) (Figure 2E-F). However, NaPyr inhibited caspase-1 activation in
BMDM infected with IAV (Figure 2G-H).
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To determine if NaPyr treatment broadly inhibited immune signaling, we treated BMDM
with lipopolysaccharide (LPS) and adenosine triphosphate (ATP), which is a potent activator of
the NLRP3 inflammasome [20]. Intriguingly, LPS+ATP treated BMDM cultured with NaPyr
produced similar amounts of IL-1β, IL-6, and TNF compared to control infected cells (Figure
3A-C). Furthermore, caspase-1 activation was not inhibited, even at higher doses of NaPyr than
used with IAV (Figure 3D-E).
To determine if NaPyr’s anti-inflammatory properties were linked to viral ligands as
opposed to bacterial ligands, we stimulated BMDM with the TLR3 ligand poly I:C (PIC).
Interestingly, BMDM treated with PIC and cultured with NaPyr produced similar amounts of IL6 compared to the untreated controls (Figure 3F).
Anti-inflammatory effects of NaPyr are associated with altered metabolism in
BMDM. Previously, NaPyr was reported to be an antioxidant with potential therapeutic uses in a
variety of inflammatory diseases [21, 22]. NLRP3 activation in many instances is dependent on
reactive oxygen species (ROS) and mitochondrial damage [23-25]. NF-κB signaling can also be
modulated by ROS [26]. Thus, we examined the antioxidant capacity of NaPyr in BMDM
infected with IAV or LPS+ATP treated BMDM by staining with the mitochondrial ROS
sensitive dye MitoSOX. IAV infection increased mitochondrial ROS generation, and addition of
NaPyr lowered mitochondrial ROS during IAV infection (Figure 4A-B). During LPS+ATP
treatment, mitochondrial ROS was elevated, but NaPyr had no effect on ROS in this setting
(Figure 4A, C). These results indicate that NaPyr inhibits ROS in a context specific manner.
IAV replication requires a massive metabolic burst to produce not only the viral
nucleotides and proteins for virus replication, but also the antiviral immune responses of the cell.
Previous research has shown that IAV induces a unique and elevated catabolic profile including
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increased lactate production [27]. Elevated lactate levels have been reported to inhibit RIG-I
signaling [11], which could explain our observations. We examined lactate production from
BMDM and observed a significant increase in lactate, a byproduct of elevated metabolism,
caused by IAV infection alone, but this was not enhanced by the addition of NaPyr (Figure 4D).
We thus hypothesized that NaPyr may fulfil a metabolic need during IAV infection, as opposed
to the formation of a byproduct. We examined intracellular ATP production by BMDMs infected
with IAV and found that IAV infection results in increased ATP levels over uninfected BMDM
or LPS+ATP treated BMDM (Figure 4E). Importantly, NaPyr treatment was able to transiently
boost ATP output from BMDM to match the need seen in IAV infected cells (Figure 4E). As the
ATP needs of IAV infected cells were not copied by LPS+ATP, NaPyr may specifically decrease
mitochondrial ROS during IAV infection by balancing metabolic stress.

Discussion
The ability of metabolites to affect the immune response to infection is an important area
of research with implications for preventing and treating disease. Recent research shows that
changes in metabolism in cells of the immune system can affect diseases such as influenza,
cancer, diabetes and more [28-30]. Our data clearly indicate that treatment of IAV infected
macrophages with NaPyr can reduce cytokines production (IL-1β, TNF-α, and IL-6). However,
NaPyr does not affect virus titer or RNA replication in macrophages. Instead, NaPyr alters the
immune function of the macrophages.
Antioxidants that can prevent mitochondrial damage also prevent NLRP3 inflammasome
activation and release of IL-1β from infected cells [23, 24]. Previous reports indicate that NaPyr
can decrease inflammation by its antioxidant potential [21, 31, 32]. Although NaPyr may
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function as a ROS scavenger, we further propose that NaPyr reduces metabolic stress and ROS
generation in an infection or disease specific manner. Specifically, pyruvate is taken into cells
and bypasses many of the regulatory checkpoints for energy metabolism such as glucose
transporters and phosphofructokinase [33, 34]. It can be directly transported into the
mitochondria for use in the TCA cycle and ATP production or used in anabolic pathways [35].
Thus, addition of NaPyr to cells increases ATP production, as we observed, and likely affects
additional metabolic pathways. In our model, we propose that decreased mitochondrial ROS is
thus a secondary, but important, anti-inflammatory effect of NaPyr treatment. There are also
additional factors that may affect the ability of NaPyr to inhibit other stimuli. In the case of
LPS+ATP treatment, the treatment duration is much shorter than IAV (only 4 hours for
LPS+ATP instead of 24 hours for IAV). Thus, intrinsic differences in the timing and pathways of
the different stimuli may further impact the effects of NaPyr and should be examined further.
In conclusion, NaPyr affects cytokine production by inhibiting inflammatory signaling
pathways and not by affecting virus growth or cell death in macrophages. Metabolic pathways
are important for cellular activation and have documented roles in immune signaling and
immune cell function [4, 6, 16, 17, 27]. Understanding the effects NaPyr has on the immune
response to IAV and other infections will help elucidate the immune response in general and
determine if certain nutrients can improve the immune response. Furthermore, severe IAV
infection in human patients is associated with a metabolic crisis (especially depleted ATP)
resulting in multi organ failure [36]. As pyruvate clearly increases ATP production, decreases
ROS and limits inflammation during IAV infection, it is worth examining as a potential
therapeutic option. Finally, severe infections with IAV and the current COVID19 pandemic are
both associated with a “cytokine storm” that results in severe immunopathology [37, 38].
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Corticosteroids are used in severe cases to suppress this overt inflammation. Importantly, the
only drug to date that has demonstrated clinical benefit for COVID19 is dexamethasone [39, 40].
Unfortunately, corticosteroids may leave the host susceptible to outgrowth of the initial pathogen
or to secondary infection [41]. As we observed no significant change in virus replication in this
model, NaPyr may have therapeutic benefit for severe IAV and other infections where excessive
inflammation is a key factor and this research warrants further investigation.
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Table 1. Antibodies.
Antibodies
Rabbit anti-mouse β-Actin

Catalog Number
Cell Signaling Technology, 8457S

Rabbit anti-mouse IкB-α

Cell Signaling Technology, 9242S

Rabbit anti-mouse Phospho-IκB-α

Cell Signaling Technology, 2859S

Mouse anti-mouse Caspase-1

Adipogen, 661228

Anti-Rabbit-HRP secondary

Jackson Immuno Res.111-035-144

Anti-mouse-HRP secondary

BioRad, HAF007
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Table 2. Primer Sequences.
Primers
Β-Actin forward

Sequence 5ʹ--3ʹ
GGCTGTATTCCCCTCCATCG

Β-Actin reverse

CCAGTTGGTAACAATGCCATGT

IL-1β forward

GACCTTCCAGGATGAGGACA

IL-1β reverse

AGCTCATATGGGTCCGACAG

TNF-α forward

CATCTTCTCAAAATTCGAGTGACAA

TNF-α reverse

TGGGAGTAGACAAGGTACAACCC

IL-6 forward

TCCAGTTGCCTTCTTGGGAC

IL-6 reverse

GTACTCCAGAAGACCAGAGG

IFN-β forward

GCCTTTGCCATCCAAGAGATGC

IFN-β reverse

ACACTGTCTGCTGGTGGAGTTC

IAV M1 forward

TGAGTCTTCTAACCGAGGTC

IAV M1 reverse

GGTCTTGTCTTTAGCCATTCC

IAV NP forward

CTCGTCGCTTATGACAAAGAAG

IAV NP reverse

AGATCATCATGTGAGTCAGAC
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Figure 1: Pyruvate inhibits cytokine responses but not virus replication. BMDM were mock
infected (untreated = UT) or infected with 10MOI influenza A/PR8/34/H1N1 virus (IAV) in the
presence or absence of sodium pyruvate (NaPyr). After 24 hours, cell culture supernatants were
collected and examined for cytokine expression by ELISA (A-C) or examined for virus titer by
plaque assay (D). Total RNA was isolated from BMDM at the indicted time points after IAV
infection in the presence or absence of NaPyr. RNA was transcribed into cDNA and qRT-PCR
performed for the indicated viral genes (E-F). BMDM were infected for 24h in the presence or
absence of NaPyr and stained with Sytox-Red then examined by flow cytometry for percentage
of cell death (G). Data are representative of 2-4 independent experiments with n=2-3 wells per
experiment. Statistical significance was determined using the students T-test for single
comparisons, one-way ANOVA with Tukey post-hoc for multiple comparisons. *** p<0.001
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Figure 2: Pyruvate inhibits immune signaling during IAV infection.
BMDM were mock infected (untreated = UT) or infected with 10MOI IAV with or without NaPyr.
Total RNA was isolated from BMDM at the indicted time points after IAV infection in the
presence or absence of NaPyr. RNA was transcribed into cDNA and qRT-PCR performed for the
indicated cytokine genes (A-D). Cell lysates were collected at the indicated time points after IAV
infection of BMDM in the presence or absence of NaPyr and examined by western blotting for
NF-κB activation (phosphorylated-IκBα) (E-F) or caspase-1 activation (Casp-1p20) after 24h (GH). Data are representative of 2-4 independent experiments with n=2-3 wells per experiment.
Statistical significance was determined using the students T-test for single comparisons, one-way
ANOVA with Tukey post-hoc for multiple comparisons. * p<0.05, ** p<0.01
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Figure 3: Immune responses to LPS+ATP are not affected by NaPyr.
BMDM were mock treated (untreated = UT) or treated with 1µM LPS for 3.5h and then treated
with 5mM ATP for 0.5h in the presence or absence of NaPyr. Culture supernatants and cell
lysates were collected after the total 4h treatment and examined by ELISA for cytokine
production (A-C) or by western blot for caspase-1 activation (Casp-1p20) (D-E). BMDM were
mock treated (untreated = UT) or treated with 25µM poly I:C (PIC) in the presence or absence of
NaPyr (F). Data are representative of 2-4 independent experiments with n=2-3 wells per
experiment. Statistical significance was determined using the students T-test test for single
comparisons, one-way ANOVA with Tukey post-hoc for multiple comparisons. No results were
significantly different.
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Figure 4: Altered immune signaling is associated with ROS and ATP levels.
BMDM were mock infected (untreated = UT) or infected with 10MOI IAV for 24h or treated
with 1µM LPS for 3.5h and then treated with 5mM ATP for 0.5h, in the presence or absence of
NaPyr. Cells were then stained with MitoSox and mitochondrial ROS levels determined by flow
cytometry (MFI=Median Fluorescence Intensity) (A-C). Cell supernatants were examined for
lactate (D) and lysates were also examined for ATP levels (E). Data are representative of 3-4
independent experiments with n=2-3 wells per experiment. Statistical significance was
determined using the students T-test for single comparisons, one-way ANOVA with Tukey posthoc for multiple comparisons. * p<0.05, ** p<0.01, *** p<0.001
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SODIUM PYRUVATE AMELIORATES INFLUENZA A INFECTION IN VIVO

Abstract
Influenza A virus (IAV) causes seasonal epidemics annually and pandemics every few
decades. Most antiviral treatments used for IAV are only effective if administered during the first
48 h of infection and antiviral resistance is possible. Therapies that can be initiated later during
IAV infection and that are less likely to elicit resistance will significantly improve treatment
options. Pyruvate, a key metabolite, and an end product of glycolysis, has been studied for many
uses, including its anti-inflammatory capabilities. Sodium pyruvate was recently shown by us to
decrease inflammasome activation during IAV infection of Bone-Marrow Derived Macrophages.
Here, we investigated sodium pyruvate’s effects on IAV in vivo. We found that nebulizing mice
with sodium pyruvate decreased morbidity and weight loss during infection. Additionally,
treated mice consumed more chow during infection, indicating improved symptoms. There were
notable improvements in pro-inflammatory cytokine production (IL-1β) and lower virus titers on
day 7 post-infection in mice treated with sodium pyruvate compared to control animals. We
conclude that pyruvate acts on the host immune response and metabolic pathways, and not
directly on the virus. Our data demonstrate that sodium pyruvate is a promising treatment option
that is safe, effective, and unlikely to elicit antiviral resistance.
Keywords: pyruvate; inflammation; influenza A virus; antiviral

Introduction
Influenza A virus (IAV) causes seasonal epidemics and periodic pandemics with
significant morbidity and mortality. In the 2019-2020 flu season, the United States Center for
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Disease Control and Prevention (CDC) estimated 38 million IAV infections and 22,000 deaths.
The most prevalent virus of the 2019-2020 season was the 2009 pandemic IAV (H1N1).
Notably, during this season, was a higher rate of infections among children aged 0-4 and adults
aged 18-49 years than in other recent seasons [1]. During pandemics, the emergence of novel
viruses can cause severe complications with increased morbidity and mortality [2]. Due to the
novelty of pandemic viruses, vaccines must be redesigned. Anti-viral therapies exist to treat IAV
[3]. However, viral resistance to these therapies is always possible. Therefore, treatments that
alter the host response to IAV infection and are less likely to result in evolution of resistance are
desirable.
Studies have shown that IAV hijacks cellular metabolisms to increase viral replication [4,
5]. Pyruvate (Pyr) (C3H4O3) is a central metabolite and key component in energy metabolism and
cellular respiration. Pyr can enter directly into the mitochondria to produce ATP via the
tricarboxylic acid cycle (TCA), which bypasses many of the metabolic regulatory pathways that
control glycolysis [6, 7]. Mitochondrial oxidative phosphorylation is the most efficient way to
produce ATP for cells. However, Pyr can also be used to make amino acids or be reduced to
lactate via fermentation or the Warburg Effect [8, 9]. Reduction of Pyr is used to replenish NAD+
and increase uptake of necessary nutrients for rapidly dividing cells, such as immune and cancer
cells [8-10]. The end goal is rapid proliferation, not energy efficiency, in most of these cases
[10].
Pyr in its many forms (ethyl Pyr, pyruvic acid, pyruvate anion, sodium pyruvate, etc.) has
been found to have many antioxidant-like benefits in several body’s systems. The molecule
seems to be well tolerated in the body with little to no toxicity [11]. Ringer’s ethyl pyruvate has
been used primarily for its increased stability in solution, however hypertonic sodium pyruvate
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has been found to more effectively protect against inflammation and stress during injury events
[12]. Additionally, Pyr has been found to have a plethora of beneficial effects on the cardiac
system [13-15]. Moreover, increasing extracellular Pyr in the brain has been found to decrease
neuronal death during traumatic brain injury events [16, 17] and be protective against neurotoxic
compounds [18]. When administered to mice of various ages, Pyr increased glycogen stores and
brain energy metabolites, which could help with diseases such as Alzheimer’s [19]. Also, Pyr
decreases epithelial permeability, inflammation, and bacterial translocation during intestinal
ischemic reperfusion (I/R) events [20, 21] Decreased damage during I/R events has also been
shown to be beneficial during organ transplantation because of decreased organ damage [22] and
damage caused by rejection following transplantation [23]. In addition to having benefits in body
systems, NaPyr has been shown to help with organ storage for transplant surgeries by decreasing
cell death, overall improved metabolism during cold storage [24, 25], and increasing graft
metabolism [26]. Red blood cell (RBC) storage has been known to generate reactive oxygen
species (ROS), but the addition of NaPyr to the storage media decreases ROS and increase
antioxidant enzymatic, SOD, activity which leads to an overall higher RBC recovery rate [27].
RBCs stored with varying levels of Pyr maintains 2,3-DPG production for longer periods of
storage [28]. Bone and tissue inflammation models have shown that Pyr treatment leads to less
destructive disease via anti-inflammatory properties [29, 30]. In relation to infectious disease,
sodium pyruvate (NaPyr) (C3H4NaO3) can improve herpes simplex 2 virus infection in vivo, and
our lab recently reported that NaPyr can regulate inflammation during IAV infection in vitro [31,
32].
In our previous study, we observed in mouse bone marrow derived macrophages
(BMDM) that NaPyr has anti-inflammatory capabilities through altered metabolism [31]. The
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addition of NaPyr to BMDM decreased mitochondrial damage in response to IAV infection.
These findings led us to further investigate NaPyr’s potential anti-viral and anti-inflammatory
capabilities in a mouse model of IAV infection. Here we show that nebulizing NaPyr in vivo in
WT C57BL/6J mice leads to decreased weight loss and increased chow intake over the course of
IAV infection. Seven days p.i., animals treated with NaPyr displayed decreased proinflammatory cytokines (IL-1β) in the lungs and decreased virus replication.

Materials and Methods
Animal Welfare. WT C57BL/6J mice were bred and raised in the Temple Hall Vivarium
at Missouri State University (Appendix C). Mice were euthanized via CO2 asphyxiation and
cervical dislocation or cardiac puncture at humane end points for tissue collection. All breeding
and experiment protocols were performed in accordance with Institutional Animal Care and Use
Committee (IACUC) guidelines (protocols 19.005, Appendix C and 19.019, Appendix A), the
AVMA Guidelines on Euthanasia, NIH regulations (Guide for the Care and Use of Laboratory
Animals), and the U.S. Animal Welfare Act of 1966.
Virus Production. The strain of IAV used in all experiments was influenza A/PR/8/34
H1N1 (PR8) (Appendix B). PR8 stocks were generated by infecting pathogen-free hen’s eggs
with 1000 PFU of PR8. Following a 3-day incubation, the allantoic fluid was harvested,
centrifuged to remove debris, and stored at -80°C for later use.
In Vivo Infection and NaPyr Treatments. Mice were anesthetized on Day 0 via
intraperitoneal injection of 80 mg/kg of Ketamine and 8 mg/kg of Xylazine. Mice were then
infected intranasally with approximately 250 PFU of influenza A/PR/8/34 H1N1, diluted in 30
mL of phosphate buffered saline (PBS). Mice used for subcutaneous (Sub-Q) injections of NaPyr
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were injected with 110mg/kg of body weight daily, divided into two doses, morning and
evening. Mice that were treated with nebulized NaPyr were treated with Emphycorp’s clinical
grade N115 (20mM NaPyr), or with 10 mM NaPyr (Fisher Bioreagents, BP356-100) diluted in
PBS, or treated with PBS alone as control. Mice were treated three times a day for 20-minute per
treatment. All mice were monitored for food/water availability and weighed daily for weight loss
and/or becoming moribund. Mice were euthanized on day 14, or day of sacrifice for tissue
samples. Chow intake was also monitored by weighing the food daily and averaging the change
in food mass by the number of animals per cage.
Tissue Collection and Processing. Mice sacrificed for tissue samples on day 3 and day 7
p.i. were euthanized via CO2 asphyxiation and cardiac puncture as an adjunct. Lungs were taken
from sacrificed mice for processing. Lungs were weighed and homogenized through a 70 mm
cell strainer (Fisherbrand, 22363548) with a final volume of 4 mL of RPMI 1640 without serum
and without NaPyr (Hyclone, SH30027.01) per tissue sample. Samples were then centrifuged
and aliquoted for future use.
Flow Cytometry for Innate and Adaptive Immune Cells. Lung homogenates were
centrifuged at 400xg for 7 minutes to achieve cell pellet. After removal of the supernatant for
other assays, red blood cells were lysed with ACK lysis buffer. Dead cells and debris were then
removed by centrifugation in 37.5% Percoll (GE Healthcare, 17-0891-02) at 2000g for 20
minutes. Cells were then stained with fluorescent antibodies (Table 1). Samples were run on the
Accuri C6 Flow Cytometer.
Viral Plaque Assay. The IAV plaque assay was performed using MDCK cells seeded at
2x105 cells/well in 12-well plates in DMEM+ 5% FBS+ 1%Pen/Strep. Ten-fold dilutions of the
virus were prepared in RPMI 1640. MDCK cells were washed with PBS twice and 100µl of each
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virus dilution added to wells in 12-well plates and incubated at 37oC and 5% CO2 for one hour.
Semisolid overlay was prepared as previously described [33]. TPCK-trypsin was added to a final
concentration of 1.0 µg/ml. After a full hour of incubation, infection medium was removed from
12-well plates, 2ml of the warm overlay with TPCK trypsin was added to each well and allowed
to solidify. Plates were turned upside down and incubated for 3 days at 37oC and 5% CO2. After
incubation, the overlay was removed, and plaques counted after staining with 1% crystal violet in
formalin.
Enzyme-Linked Immunosorbent Assay (ELISA). Supernatant from homogenized lung
tissue samples were analyzed for IL-1β and IL-6. ELISA kits were purchased from Ebioscience
(88-7013-88, 88-7064-88) and assays performed according to the manufacturer’s
recommendations. Plates were read at 450nm on a microplate reader (BioTek ELx808). Cytokine
levels were normalized to lung mass/ml.
Statistical Analysis. Statistical analysis was performed using GraphPad PRISM9. For In
Vivo weight loss and chow consumption during experiments, a two-way ANOVA was performed
(time and treatment effects). For viral titer, cytokine and cell populations analysis, a Student’s ttest was performed. A p-value <0.05 was considered statistically significant.

Results
NaPyr is not toxic In Vivo. N115 is a clinical grade nasal spray containing 20mM NaPyr
that has undergone safety and phase I, phase II and phase III clinical trials. The FDA is currently
reviewing the administration of N115 for use in COPD patients with Idiopathic Pulmonary
Fibrosis, or Idiopathic Pulmonary Fibrosis Patients alone (EmphyCorp, Cellular Sciences Inc
FDA submissions). Patient surveys indicated that use of N115 may decrease the incidence,
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symptoms, and duration of respiratory infections too. Millions of patients have been treated with
N115 nasal spray in over 200 hospitals globally, which includes pregnant women, patients with
allergic rhinitis, COPD patients, sinusitis, and patients with pulmonary fibrosis, with no adverse
events reported. The use of the nasal spray in these patients demonstrates its safety and efficacy
and the ability of NaPyr to reduce nasal congestion and inflammation. In a Phase III Placebo
Controlled Clinical Trial with Idiopathic Pulmonary Fibrosis Patients, the N115 nasal spray
demonstrated a statistically and clinically significant increase in nasal nitric oxide, the volume of
air exhaled at the end of the first second of forced expiration (FEV-1), SaO2, the volume of air
exhaled during forced expiration (FVC), FEV-1/FVC ratios (52% to 86%). N115 reduced
hypoxemia, and it also reduced lung inflammation, inflammatory cytokines, and coughing. Other
studies confirm the safety of supplementation with NaPyr [11, 17, 34].
Based on these promising data, we sought to examine the effectiveness of NaPyr for
treatment of IAV infection. We conducted preliminary toxicity experiments using nebulized
NaPyr at 10mM and 1M concentrations made in-house using Fisher Bioreagents NaPyr (BP356100) diluted in PBS, or just PBS for a control. We found no noticeable weight loss in mice
treated with 10mM NaPyr. However, 1M NaPyr treatment did show some slight decline in
weight of mice, but this was likely due to the cloud produced by nebulizing 1M NaPyr, which
was thick like chalk dust and difficult to breathe (Figure 1A). Overall, NaPyr was not found to be
toxic at the concentrations used for the treatment of IAV infected mice.
Nebulized NaPyr improves weight loss in IAV infected mice. Our previous research
with NaPyr in vitro established its immunomodulatory properties [31]. We, therefore, examined
its effects in mice infected with IAV. WT C57BL/6J mice (n = ???) were infected with 250PFU
of influenza A/PR/8/34 H1N1 virus and injected sub-cutaneously (Sub-Q) with 55mg/kg of
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NaPyr twice a day for 14 days (n = ??) and compared to PBS injection controls (n = ??).
Although injection of NaPyr resulted in increased food intake early and late during infection, it
did not significantly improve weight loss in IAV infected mice (Figure 2A-B). Thus, we began
looking for an alternative, more direct, administration method during infection. Aerosols are
used frequently for treatment of lower respiratory infections, more specifically, viral pneumonia
[35]. Hence, we hypothesized that a nebulization model would be a more direct route to the site
of infection. treating mice three times a day with nebulized 10mM NaPyr for approximately 15minute intervals, resulted in less weight loss and increase in food intake (Figure 2C-D:these data
are combined from 2 independent experiments with n=4-5 mice per treatment group per
experiment). Two-way ANOVA p=0.0399, 0.0043, 0.0116, and 0.0363 for days 5-8 in Figure
2C, Two-way ANOVA p=0.0199 and 0.0093 for days 2-3 in Figure 2D in relation to indicated
treatment).
N115 decreases weight loss and increases chow intake during IAV infection. As
stated above, EmphyCorp manufactures a stable 20 mM NaPyr nasal spray (N115). In Phase
I/II/III clinical trials, N115 has demonstrated promising results in decreasing lung inflammation
in COPD and Idiopathic Pulmonary Fibrosis patients. Using N115, we examined potential
toxicity, but observed no difference in weight loss between uninfected WT C57BL/6J mice
treated with N115 compared to PBS controls (Figure 3A). Next, we examined weight loss in
mice infected with 250PFU of influenza A/PR/8/34 H1N1 virus and treated three times a day for
20-minute intervals. Our results indicate that nebulizing mice with N115 over the course of 12
days of IAV infection decreased weight loss (days 7-14) and increased chow intake (days 9-10),
compared to the PBS controls (Figure 3B-3C). (Weight loss and chow intake data are combined
from 3 independent experiments with n=4-6 mice per treatment group per independent
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experiment. Two-way ANOVA p=0.0127, 0.0012, 0.0002, <0.0001, 0.0005, 0.0046, 0.0233,
0.0311 for days 7-14 respectively in Figure 3B. Two-way ANOVA p=0.0492 and 0.0335 for
days 9-10 in Figure 3C when looking at treatments day by day).
As N115 improved weight loss, we next examined the cause for improved weight loss.
We investigated viral titers by plaque assay on Day 3, before weight loss, and Day 7 p.i., just as
the N115 treated mice started to show improvement in weight loss. We found that there was
significantly less virus in the lungs of N115 treated mice compared to PBS treated controls on
Day 7 (Figure 3D-E). (Viral titer data are combined from 2 individual experiments with 3-5 mice
per treatment group per experiment. Statistical significance was determined using a Student’s Ttest, p=0.0172 for figure 3E.)
As previously reported in vitro [31], we also observed significantly less IL-1β levels in
the lungs of N115 treated mice (Figure 4A-B). Despite lower IL-1β levels, most leukocyte
numbers were similar in the lungs of N115 and PBS treated mice, except for inflammatory
monocyte numbers, which were elevated in the N115 mice (Figure 4C-D). Overall, N115
appears to decrease disease during IAV infection by decreasing virus titers and lowering
inflammatory cytokine levels. (Data in Figures 4A-D are combined from 2 independent
experiments with n=3-5 mice per experiment. Statistical significance was determined using a
Student’s T-test. Figure 4A p=0.00672 for IL-1β; Figure 4B p=0.0351 for IL-1β; Figure 4C
p=0.0442 for inflammatory monocytes).
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Discussion
Due to the evolution of antiviral or antibiotic resistance, the development of therapies that
target host pathways to disrupt pathogen replication or disease is an avenue worthy of
exploration. Some cellular metabolites can alter inflammation or pathogen replication, but our
data suggest that the route of administration is important. Our data indicates that sub-Q injection
of NaPyr does not influence IAV induced weight loss. However, nebulizing NaPyr does have a
significant impact on weight loss, virus titer, and cytokine production during IAV infection in
vivo in mice. Since Pyr can be rapidly absorbed by virtually any cell, injected NaPyr is likely
taken up by other cells before reaching the target cells in the IAV infected lung [36, 37]. Most
IAV antiviral treatments target specific proteins within the virus. These proteins are prone to
mutations and resistance to such drugs. Certain strains of IAV are known to be resistant to the
M2 and neuraminidase inhibitors [38]. Since NaPyr affects cellular metabolism and
inflammation instead of directly targeting virus replication, there is a much lower chance that the
virus will develop resistance to NaPyr treatment. Influenza and COVID-19 are known to cause
mortality and morbidity in the elderly and immunocompromised. However, it is often forgotten
that both diseases afflict children, usually with mild symptoms. In rare cases, there is mortality
caused by complications during IAV infection. Seasonally, influenza causes 7,000-26,000
hospitalizations in children under five years old [39]. COVID-19 this year has resulted in 3,240
hospitalizations in school-aged children [40]. As of 23-Feb-2021, 51 children, aged less than 18,
have died in the United States from complications with COVID-19 [40]. Comparatively, the
CDC has reported a range of 37-188 deaths annually in children under five years old from
complications caused by influenza infections [39]. Our data in this manuscript clearly
demonstrate that N115 improves influenza disease. Furthermore, we have preliminary data that
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suggest it may work similarly during other respiratory virus infections including
COVID19/SARS-CoV-2. Proactive treatment with NaPyr is not toxic and could be of benefit to
children that are afflicted by many respiratory viruses.
As previously noted in vitro, the addition of NaPyr reduces mitochondrial ROS, in turn
reducing mitochondrial damage during the course of IAV infection [31]. This reduction could
indicate decreased NLRP3 inflammasome activation, which would further explain why IL-1β is
lower in the mice treated with N115. Further studies would be necessary to verify that NaPyr is
modulating the NLRP3 inflammasome in vivo. However, in vitro we demonstrated that addition
of NaPyr to the infection media of BMDMs led to lowered caspase-1 activation and decreased
pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) [31]. Presumably, this would be a similar
mechanism in vivo to be explored with mice treated with N115. Future directions would include
investigating whether nebulized NaPyr:
a) influences lasting immunity following IAV infection,
b) alters or diminishes lung damage caused by IAV infection,
c) protects against severe disease cases,
d) is acting as an immunomodulator as we demonstrated in vitro.
It is also not clear how NaPyr affects virus replication. We reported that NaPyr does not
affect virus replication in macrophages in vitro [31], and we have examined IAV replication in
MDCK cells in vitro and found no effect of NaPyr either (data not shown). One possible
explanation is that NaPyr alters immune cell function, such as enhanced Th1 responses. This
would agree with the timing observed in our experiments where virus titers were only lower on
Day 7 and weight loss was improved after day 7 too. Alternatively, NaPyr may elicit a response
from respiratory epithelial cells that is antiviral such as NO production or increased interferon
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responses. Duplicating the viral replication in both respiratory epithelial cell lines and other
innate immune cells is needed to further address these questions. Another potential avenue would
be to explore carbon tracing to determine where NaPyr is being shuttled during the IAV
infection. More studies would have to be done to confirm NaPyr, or N115’s ability to ameliorate
IAV infection in other model organisms such as ferrets. Notably, N115 is currently in human
clinical trials for a multitude of inflammatory lung diseases including chronic obstructive
pulmonary disorder and COVID-19. These clinical trials may also shed light on the mechanisms
involved during IAV infection.
In conclusion, we show that nebulizing mice with sodium pyruvate decreased morbidity
and weight loss during infection. Additionally, treated mice consumed more chow during
infection indicating improved disease symptoms. There were notable improvements in proinflammatory cytokine production (IL-1β) and lower virus titers on days 7 post infection (p.i.) in
mice treated with NaPyr compared to control animals. As NaPyr appears to act on the host
immune response and metabolic pathways and not directly on the virus, sodium pyruvate is a
promising treatment option that is safe, effective, and unlikely to elicit antiviral resistance.
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Table 1. Fluorescent antibodies used for FACS staining in preparation for flow cytometry.

FITC

Monocyte
Stain
CD11c

PE

Gr1

50-5931-U100

CD8

100707

PerCP 5.5

CD3ε

65-0031-U100

CD3ε

65-0031-U100

APC

CD11b

20-0112-U100

CD19

115511

Fluorophore

Cat#

Lymphocyte Stain Cat#

35-0114-U100

CD4

35-0042-U100

Antibodies were purchased from Tonbo (San Diego, CA, USA) or Biolegend (San Diego, CA,
USA).
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Figure 1. Sodium pyruvate (NaPyr) shows no toxicity in mice. WT C57BL/6J mice were
nebulized 3 times daily for 15 min per treatment with 10 mM and 1 M concentrations of NaPyr
diluted in phosphate buffered saline (PBS) for 14 days to determine toxicity and weight
differences between treatment groups. Data are representative of one experiment with n = 5 mice
per treatment group.
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Figure 2. Effects of injection or nebulization of NaPyr on influenza A virus (IAV) infection. WT
C57BL/6J mice were infected intranasally with 250 PFU of influenza A/PR/8/34 H1N1. Mice
were treated as indicated and monitored daily for 14 days to determine survival and weight
differences between treatment groups. (A) Weight loss was examined in mice injected Sub-Q
with 55 mg/kg NaPyr twice a day for 14-days compared to PBS injected mice. (B) Average
chow intake over the 14-day IAV infection of both Sub-Q NaPyr treated and PBS treated mice.
(C) Mice were treated 3 times a day with either nebulized 10 mM NaPyr or nebulized PBS as
control. Weight loss differences viewed over the 14-day IAV infection of both NaPyr treated and
PBS treated mice. (D) Average chow intake over the 14-day IAV infection of both nebulized 10
mM NaPyr and PBS treated mice. Data are representative of 2–3 individual experiments with n =
4–5 mice per treatment group per independent experiment. Statistical significance was
determined using a Two-way ANOVA with Fisher LSD post-hoc for multiple comparisons. * p
< 0.05, ** p < 0.01.
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Figure 3. Nebulized N115 improves weight loss and virus titer in mice infected with IAV. WT
C57BL/6J mice were treated with either nebulized 20 mM NaPyr (N115) or nebulized PBS as
control 3 times a day for 20 min/treatment to test for toxicity (A). WT C57BL/6J mice were
infected intranasally with 250 PFU of influenza A/PR/8/34 H1N1. Mice were treated with either
nebulized 20 mM NaPyr (N115) or nebulized PBS as control 3 times a day for 20 min/treatment.
(B) Mice were monitored daily for 14 days to determine weight differences between treatment
groups. (C) Average chow intake over the 14-day IAV infection of both N115 treated and PBS
treated mice. (D–E) Viral titer was assessed by plaque assay on day 3 (D) and day 7 (E) p.i. from
lung homogenates. Weight loss and chow intake data are representative of 3 independent
experiments with n = 4–6 mice per treatment group per independent experiment. Viral titer data
are representative of 2 individual experiments with 3–5 mice per treatment group per individual
experiment. Statistical significance was determined using a Two-way ANOVA with Fisher LSD
post-hoc for multiple comparisons, and Student’s t-test for single comparisons. * p < 0.05, ** p <
0.01, *** p < 0.001.

53

Figure 4. N115 treatment modulates inflammatory responses during IAV infection. WT
C57BL/6J mice were anesthetized and infected with 250 PFU of influenza A/PR/8/34 H1N1.
Mice were treated 3 times a daily for 20 min/treatment with either nebulized 20 mM NaPyr
(N115) or nebulized PBS as control. Mice were euthanized on day 3 (A) or day 7 p.i. (B–D) for
tissue collection. Lung samples were then homogenized and examined via ELISA for cytokine
production (A–B) or cellular infiltration into the lungs by flow cytometry (C–D). Data are
combined from 2 independent experiments with n = 3–5 mice per experiment. Statistical
significance was determined using a Student’s t-test for single comparisons. * p < 0.05, ** p <
0.01.
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DISCUSSION

The easiest way to prevent influenza infection is to get vaccinated. The influenza vaccine
was 45% effective during the 2019-2020 influenza season [38]. If we recall, only 48.4% of the
United States population, 18 years or older, received the vaccine in the 2019-2020 influenza
season [2]; therefore, there is an inherent need for other options to ameliorate the disease
associated with IAV infection. These include but are not limited to anti-viral therapies, home
remedies, and corticosteroid treatments.
As of 17-Mar-2021, there are four pharmaceutical anti-viral treatments that are FDA
approved for treatment of IAV on the market: oseltamivir, zanamivir, peramivir,
and baloxavir marboxil [39]. All of these treatments must be administered early in the infection
and can be prescribed prophylactically in unvaccinated individuals [39, 40]. Oseltamivir,
zanamivir, and peramivir are effective on influenza A and B and work by inhibiting the
neuraminidase (NA) on the virus’s surface, thus preventing, or dysregulating, the release of the
viral particles and reinfection inhibition caused by the NA during functional viral replication [4144]. Viral resistance has been observed in each of these three therapies [41, 45-48]. Targeting a
different part of the influenza virus, baloxavir marboxil, prevents transcription of the viral
RNA [49]. Interestingly, a combination therapy of an NA inhibitor and baloxavir marboxil leads
to decreased viral titer in mice at multiple time points post infection. This could lead to a potent
combination therapy option up to 96 hours post infection [50]. Previously, M2 inhibitors,
rimantadine and amantadine were used to treat IAV infection and worked by preventing viral
replication because they altered the M2 ion channels. The caveat to both of these treatments is
they only functioned on influenza A virus, not influenza B virus. Many strains of IAV are now
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resistant to both rimantadine and amantadine. The United States no longer recommends either
M2 inhibitor for treatment of IAV [43].
Home remedies would include quarantining during infection, staying hydrated, rest, and
over the counter pain relievers [51]. Each of these treatments have their own set of downfalls.
Additionally, corticosteroid treatment decreases inflammation and is a potent immunomodulator,
but has been shown to have adverse effects in severe cases of IAV infection [44]. In addition,
using corticosteroid treatment compromises the immune response and leaves the body prey to
other opportunistic pathogens, creating coinfections [52-55].
The current pharmaceutical antiviral remedies are limited by their capacity to become
like the M2 inhibitors insofar that they could be phased out due to antigenic drift or shift. This
sets the stage, and the need, for alternative antiviral therapies that are not as susceptible to
antiviral resistance. As noted, the anti-viral treatments above are for the use of influenza viruses,
and in some instances only specific strains of influenza virus. Antioxidants have long been
studied for their ROS scavenging abilities and their influence on influenza infection in cases of
antiviral resistance. Antioxidants scavenge the superoxide produced by innate immune cells,
namely macrophages, thus reducing ROS and oxidative stress observed during infection [56-58].
Treating with antioxidants may also treat other viruses, such as SARS-CoV-2, that induce
cytokine storms or hyper ROS production. NaPyr has been shown to have antioxidant
properties [59-61], but we did not observe any benefit in adding NaPyr to in vitro studies with
other pathogens, such as E. coli. Sodium pyruvate has been shown to have anti-inflammatory
activity within moderate and chronic models of inflammation [62-65]. Additionally, Pyr is
secreted into serum of cultured cells exposed to H2O2, suggesting Pyr is naturally exported to
act as an antioxidant [59, 66].
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However, many questions still surround our findings. We observed in vitro that overall
ROS and mitochondrial ROS are decreased; more tests are necessary to determine if this is the
case in vivo. In vitro we experimented on terminally differentiated macrophages, which are
innate immune cells, but what cells are being affected in vivo is still a mystery. Potentially, this
could be answered by testing cytokine levels, viral replication, and ROS production in other
epithelial cell lines, such as lung epithelial cells. Nitric oxide, which is produced by neutrophils
at the onset of influenza infection, could also be targeted by sodium pyruvate’s antioxidant
properties. In vivo, there are many things that could still be done, testing for interferons and what
exactly NaPyr is immunomodulating in the whole system. Another interesting feature of our in
vitro work is that in the BMDMs, we observed a significant decrease in interferon (IFN)-β
production, which reduces antigen presentation and allows for immune suppression [67]. This
decrease in BMDMs would explain the decreased viral titer seen on day 7 in vivo due to
increased T cell responses, but what does lasting immunity to IAV look like
with NaPyr treatment? Presumably the treatment would provide the same immunity as an
untreated infection or any other treated infection, but with a decrease in IFN- β and decreased
viral titer, is the adaptive immune system being primed appropriately for subsequent infections?
Noting that according to our data, adaptive immune cells are slightly elevated in mice treated
with NaPyr during IAV infection, which would potentially mean a more robust adaptive immune
response. Thus, leaving a more potent antibody response to subsequent IAV infections. Overall,
our findings indicate that NaPyr is a potential therapeutic treatment for IAV with little chance of
developing antiviral resistance and no negative side effects for the host.
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